The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

Columnist Dagmar Munn has a Santa wish list for her outings over the holidays: accessible restrooms and good cutlery among ...

The world's largest ALS patient-derived stem cell and biodata repository is now available to researchers globally.

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...

A grant from the ALS Association will fund an early-stage clinical trial to test Tiziana's foralumab nasal spray in 20 ALS ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

Although she did everything possible to learn about ALS, columnist Juliet Taylor says the disease often left her feeling ...

A newly awarded grant from the ALS Association will support Asha Therapeutics' work to advance ASHA-624 into a first-in-human ...

Lately columnist Dagmar Munn has been feeling unmotivated and exhausted, but she has several strategies that help her get out ...

Columnist Kristin Neva recognizes the distinction between being thankful "in" a bad situation rather than "for" a bad situation.